Authors
Latest:
Steps to Successful Management of Immunotherapy ToxicitiesEzra Cohen, MD, FRCPSC, FASCO, discusses the most important parts of successfully managing toxicities related to treatment with immunotherapy.
Latest:
Different Therapeutic Options Required for Subtypes in Mantle Cell LymphomaEzzat Elhassadi, MD, a consultant hematologist at the University Hospital Waterford in Ireland, discusses the therapeutic approach for different subtypes of mantle cell lymphoma. MCL is a spectrum of diseases that should be treated differently, he says.
Latest:
Using Platinum Agents in Different Settings of TNBCFabrice André, MD, PhD, professor in the Department of Medical Oncology at the Institut Gustave Roussy in Villejuif, France, addresses questions regarding the use of platinum regimens for patients with triple-negative breast cancer (TNBC). He discusses 2 platinum agents, cisplatin and carboplatin, and when it is recommended that these agents be used.
Latest:
Molecular Profiling in NSCLCFabrice Barlesi, MD, discusses the importance of molecular testing in patients with nonsquamous non–small cell lung cancer during the World Conference on Lung Cancer in Toronto, Canada.
Latest:
Rationale for Phase I Study of AMG 330 in Relapsed/Refractory AML<br /> Farhad Ravandi-Kashani, MD, The University of Texas MD Anderson Cancer Center, discusses the rationale for targeting CD33 with AMG 330 in patients with relapsed/refractory acute myeloid leukemia.
Latest:
Dr. Farhad Ravandi on How to Treat Minimal Residual DiseaseFarhad Ravandi, MD, Professor in the Department of Leukemia, MD Anderson Cancer Center‎, discusses minimal residual disease. Ravandi says historically, MRD has shown a resistance to cytotoxic chemotherapy.
Latest:
Acalabrutinib With/Without Obinutuzumab Shows Survival Benefit in CLLFarrukh Awan, MD, discusses the results of the phase 3 ELEVATE-TN trial of acalabrutinib in patients with chronic lymphocytic leukemia.
Latest:
The Biggest Issue with Treatment of Breast Cancer in MenFatima Cardoso, MD, medical oncologist at the Champalimaud Clinical Centre in Portugal, explains the biggest issue in treatment of male breast cancer is due to lack of education. Male patients are most commonly diagnosed in the advanced stages because of this and are commonly given the wrong treatments, says Cardoso.
Latest:
The Importance of Urine Tests for Mutation DetectionFilip Janku, MD, PhD, assistant professor, Department of Investigational Cancer Therapeutics, University of Texas, MD Anderson Cancer Center, discusses the importance of having a urine test to detect for cancer mutations.
Latest:
Combination Regimens May Improve Responses in Ovarian CancerFloor J. Backes, MD, discusses the immunotherapeutic options available for treatment of patients with ovarian cancer.
Latest:
Thyroid Hormone Receptor and Runx2 Expression in Thyroid Cancer CellsFrances Carr, PhD, professor, Department of Pharmacology, The University of Vermont, discusses the relationship between the thyroid hormone receptor and Runx2 expression in thyroid cancer cells.
Latest:
The Use of Arsenic Trioxide in Acute Promyelocytic LeukemiaFrancesco Lo-Coco, MD, Hematology, University Tor Vergata, speaks at the 2012 American Society of Hematology annual meeting about the use of arsenic trioxide in acute promyelocytic leukemia.
Latest:
Findings of a Biosimilar Trastuzumab Study in Patients with HER2-Positive Breast CancerFrancisco Esteva, director, breast medical oncology program, Perlmutter Cancer Center, NYU Langone Medical Center, discusses the findings of a biosimilar trastuzumab study in patients with HER2-positive breast cancer.
Latest:
The Emerging Role of Obinutuzumab in the Treatment of B-Cell Lymphoid MalignanciesMonoclonal antibodies (mAbs) that target key “restricted†antigens in cancer cells have become an integral part of the management of multiple hematologic and solid tumor malignancies.
Latest:
The Impact of <em>BRCA</em> Mutations in Ovarian CancerFranco M. Muggia, MD, professor of oncology, New York University, director, Division of Medical Oncology, New York University Medical Center, discusses the impact of BRCA mutations in ovarian cancer.
Latest:
A Study on Two Adjuvant Trials in Patients With Stage III Colon CancerFrank A. Sinicrope, MD, medical oncologist, Departments of Gastroenterology and Hepatology and Oncology, Cancer Center, Mayo Clinic discusses a study on two adjuvant trials in patients with stage III colon cancer.
Latest:
Keep Vigilant for Signs of Peripheral Neuropathy in Relapsed/Refractory Diffuse Large B-Cell LymphomaEfficacy analyses by cell of origin and by MYC and BCL2 double expression status showed a trend toward improved outcomes of patients treated on the polatuzumab vedotin-containing arm regardless of cell of origin or MYC and BCL2 doubkle expression status.
Latest:
Dr. Frank Sinicrope on Further Study into Different Types of Colon CancerFrank A. Sinicrope, MD, talks about sporadic mismatch repair deficient colonic cancer tumors compared to familial related to germ line mutations in the setting of Lynch syndrome.
Latest:
Challenges With Neoadjuvant Endocrine Therapy in Breast CancerFrankie Ann Holmes, MD, Texas Oncology, discusses challenges with neoadjuvant endocrine therapy in breast cancer.
Latest:
Dr. Kass Discusses HER2-Positive Breast Cancer AdvancementsFred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, discusses HER2-positive breast cancer advancements.
Latest:
Genomic Testing Expands With Evolving Lung Cancer Treatment ParadigmFred R. Hirsch, MD, PhD, discusses how genomic testing has expanded over the last few years and has impacted the lung cancer treatment paradigm.
Latest:
Olaparib Plus Abiraterone Improves rPFS Across Biomarker Groups for mCRPCFred Saad, MD, FRSC, discusses the findings of a biomarker analysis of the PROpel trial in patients with metastatic castration-resistant prostate cancer.
Latest:
The Optimal Use of Identifying Genetic Risk Factors in Prostate CancerFred Schumacher, PhD, MPH, associate professor, Case Western Reserve University, discusses a study that highlights the optimal use of the identification of genetic risk factors in prostate cancer, as well as the biology of developing prostate cancer.
Latest:
Dr. Frederic Amant on the Safety of Chemotherapy During PregnancyFrederic Amant, MD, PhD, assistant professor, gynecologic oncologist, head of the scientific section of gynecologic oncology at Katholieke Universiteit in Leuven, Belgium, the impacts of chemotherapy on pregnant woman and their babies.
Latest:
An Analysis of the SALT 1 and SALT 2 StudiesFrederick Alan Rapoport, MD, discusses the results of the SALT 1 and SALT 2 studies, which measured the efficacy of tolvaptan (Samsca) in patients with euvolemic and hypervolemic hyponatremia
Latest:
Unmet Needs in MCLFrederick Locke, MD, addresses the ongoing unmet needs for patients with mantle cell lymphoma such as the role of novel agents in the upfront setting.
Latest:
Assessing Available CAR T-Cell Agents for DLBCLFrederick Locke, MD, reviews the current landscape of approved CAR T-cell therapies for patients with large B-cell lymphoma and how off the shelf options like ALLO-501 and ALLO-501A can fill the gap for patients waiting for treatment.
